Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Xenon Pharmaceuticals Inc XENE

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the... see more

Recent & Breaking News (NDAQ:XENE)

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

GlobeNewswire January 13, 2020

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

GlobeNewswire December 6, 2019

Xenon Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference

GlobeNewswire December 3, 2019

Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update on License and Collaboration Agreement with Neurocrine Biosciences

GlobeNewswire December 2, 2019

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

GlobeNewswire December 2, 2019

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

PR Newswire December 2, 2019

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire November 15, 2019

Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire November 5, 2019

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Provide Corporate Update

GlobeNewswire October 29, 2019

Encode Ideas, L.P. Announces the Initiation of Research Coverage on Xenon Pharmaceuticals Inc.

Newsfile October 16, 2019

Xenon Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

GlobeNewswire September 25, 2019

Xenon Announces Appointment of Shelley McCloskey as Senior Vice President, Human Resources

GlobeNewswire September 17, 2019

Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion's Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain

GlobeNewswire September 9, 2019

Xenon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire August 6, 2019

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Provide Corporate Update

GlobeNewswire July 31, 2019

Xenon Pharmaceuticals Presents Corporate Update on Neurology-Focused Pipeline at the Jefferies 2019 Healthcare Conference

GlobeNewswire June 5, 2019

Xenon Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

GlobeNewswire May 29, 2019

Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire May 7, 2019

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Provide Corporate Update

GlobeNewswire April 30, 2019

Xenon Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 24, 2019